Modulation of vascular inflammation by PPARs

Doris M. Tham, Yi Xin Wang, John C Rutledge

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.

Original languageEnglish (US)
Pages (from-to)109-116
Number of pages8
JournalDrug News and Perspectives
Volume16
Issue number2
DOIs
StatePublished - Mar 2003

Fingerprint

Peroxisome Proliferator-Activated Receptors
Blood Vessels
Inflammation
Atherosclerosis
Anti-Inflammatory Agents
Monocytes
Endothelial Cells
Macrophages
Foam Cells
Cell Adhesion Molecules
Metalloproteases
Vascular Smooth Muscle
Chemokines
Smooth Muscle Myocytes
Lymphocytes
Cytokines
Gene Expression
Genes
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Modulation of vascular inflammation by PPARs. / Tham, Doris M.; Wang, Yi Xin; Rutledge, John C.

In: Drug News and Perspectives, Vol. 16, No. 2, 03.2003, p. 109-116.

Research output: Contribution to journalArticle

Tham, Doris M. ; Wang, Yi Xin ; Rutledge, John C. / Modulation of vascular inflammation by PPARs. In: Drug News and Perspectives. 2003 ; Vol. 16, No. 2. pp. 109-116.
@article{04313e6109994353ba3ef6bbb5296530,
title = "Modulation of vascular inflammation by PPARs",
abstract = "The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.",
author = "Tham, {Doris M.} and Wang, {Yi Xin} and Rutledge, {John C}",
year = "2003",
month = "3",
doi = "10.1358/dnp.2003.16.2.740244",
language = "English (US)",
volume = "16",
pages = "109--116",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Modulation of vascular inflammation by PPARs

AU - Tham, Doris M.

AU - Wang, Yi Xin

AU - Rutledge, John C

PY - 2003/3

Y1 - 2003/3

N2 - The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.

AB - The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=0037933426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037933426&partnerID=8YFLogxK

U2 - 10.1358/dnp.2003.16.2.740244

DO - 10.1358/dnp.2003.16.2.740244

M3 - Article

C2 - 12792672

AN - SCOPUS:0037933426

VL - 16

SP - 109

EP - 116

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 2

ER -